Bringing a new drug to market in the Eurasian Economic Union is a strategic move for any pharmaceutical company. With a single regulatory framework across five member states — Russia, Armenia, Belarus, Kazakhstan, and Kyrgyzstan — marketing authorization in one country unlocks access to all five, covering a total population of 186 million people.
For sponsors looking to expand efficiently, the EAEU offers a streamlined, rule-based approval process. Understanding the timeline and key milestones is critical to successful market entry.
Let us walk you through the unified drug registration procedure using Russia as the reference country. Understanding these steps will help you prepare for what lies ahead.
The process begins with dossier submission to the Ministry of Health of the Russian Federation. This is the official start of your registration journey in the EAEU. Once submitted, the reference country (Russia) conducts a full dossier expertise. During this phase, the authorities review your drug's quality, efficacy, and safety data in detail. At the same time, a separate GMP inspection is carried out by the Ministry of Industry and Trade of the Russian Federation. Both activities run in parallel and take approximately 11 months to complete. Upon successful completion of the expertise, the reference country issues an expertise report confirming drug registration. This report becomes the cornerstone for gaining access to the other four EAEU member states. The final stage is recognition by other EAEU countries. Each of the remaining member states (Armenia, Belarus, Kazakhstan, and Kyrgyzstan) reviews the reference country's expertise report along with their own country‑specific Module 1 documentation. This recognition phase takes 100 working days.
In short, the unified procedure allows you to obtain marketing authorization in Russia first and then expand to the entire EAEU market without starting from scratch in each country.
With deep local expertise and a proven track record as a CRO Russia and across the EAEU, OCT CRO provides end-to-end drug registration services to help you navigate the unified procedure efficiently. We offer full-spectrum support, including:
OCT CRO’s in-house team provides expert medical writing services tailored to EAEU standards: from clinical study reports and investigator brochures to patient-facing documents and SmPCs. Clear, compliant, and submission-ready documentation is a cornerstone of successful registration.
Entering the Russian and EAEU pharmaceutical market from China comes with unique challenges, from differing regulatory standards and language barriers to cultural nuances in communication with local authorities. OCT CRO understands these challenges firsthand and has built a bridge that helps Chinese companies succeed. Here is why leading Chinese pharmaceutical companies trust OCT:
With OCT CRO, you are not just hiring a service provider. You gain a dedicated team that treats your success as our own, smoothly, compliantly, and with a clear return on investment.
Whether you are planning your first registration or expanding an existing portfolio, OCT CRO will guide you every step of the way. Contact us for a consultation: info@oct-cro.com. Take the first step toward unified registration across 186 million patients, efficiently, transparently, and with a partner you can trust.
